Holen Sie sich die Stockscreener-App
29.93
2.32%
-0.71
Schlusskurs vom Vortag:
$30.64
Offen:
$29.83
24-Stunden-Volumen:
5.49M
Relative Volume:
0.54
Marktkapitalisierung:
$6.98B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
57.33
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+1.56%
1M Leistung:
+8.80%
6M Leistung:
+41.51%
1J Leistung:
-45.31%
1-Tages-Spanne:
$28.72
$30.38
1-Wochen-Bereich:
$27.49
$31.79
52-Wochen-Spanne:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.93 | 6.98B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.26 | 48.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.465 | 41.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.17 | 31.06B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.40 | 23.48B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-11 | Fortgesetzt | JP Morgan | Neutral |
| 2026-05-12 | Bestätigt | Needham | Buy |
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Hims & Hers Health: The Bullish Case Is Hard To Forecast, But It Is Asymmetrical - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
Should You Trim Or Add To Your Hims & Hers Position Now? - Trefis
Kaplan Fox Notifies Hims & Hers Health, Inc. (NYSE: HIMS) Investo - The National Law Review
Hims & Hers Launches Hers Women’s-Health Platform in Australia - www.tokenpost.com
Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026 - HIMS investor relations
Hims & Hers (HIMS) Launches Hers Brand in Australia, Expanding W - GuruFocus
Hers Launches in Australia, Built to Care for the Whole Woman - Business Wire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
Hims & Hers Health, Inc. (HIMS) Stock Forecasts - Yahoo Finance
Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud - GlobeNewswire
Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply LowerHBSS - GlobeNewswire Inc.
Hims & Hers Health climbs 10% amid recent volatile trading (HIMS:NYSE) - Seeking Alpha
Hims & Hers Health Jumps 7.3% Amid Sector-Wide Rally - AlphaStreet
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - WBOC TV
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now - The Globe and Mail
Hims & Hers Health Shares Slide as Investors Weigh Accounting Leadership Change and Ongoing Margin Questions - Quiver Quantitative
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now - Zacks Investment Research
Kaplan Fox Alerts Hims & Hers Health, Inc. (NYSE: HIMS) Investors - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming DeadlinesHIMS - PR Newswire
Major Shuffle at Hims & Hers - TradingView
Kaplan Fox Advises Investors of Hims & Hers Health, Inc. (NYSE: H - The National Law Review
Hims & Hers Health (HIMS) Names Jon Franklin as Chief Accounting Officer Amid Financial Oversight Focus - GuruFocus
Hims & Hers Health Names Jon Franklin Chief Accounting Officer (HIMS) - GuruFocus
Hims & Hers Health Names New Principal Accounting Officer - TipRanks
Hims & Hers Names Jon Franklin as Chief Accounting Officer - HIMS investor relations
Hims & Hers Names Jon Franklin as Chief Accounting Officer - Business Wire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit - Morningstar
Hims & Hers Health (HIMS) Investment Thesis: Capturing Market Share in the Cash-Pay Space - Yahoo Finance
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - GlobeNewswire Inc.
Hims & Hers Health, Inc. Securities Fraud Class Action - GlobeNewswire
AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - GlobeNewswire Inc.
Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Hims & Hers Health Stock Forecast | FDA GLP-1 Warning - Capital.com
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
How Investors May Respond To Hims & Hers Health (HIMS) Appointing Regional Chief Medical Officers For Global Expansion - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Hims & Hers Health (HIMS) CFO Oluyemi Okupe Sells 2,000 Shares - GuruFocus
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE - The National Law Review
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
Kaplan Fox Notifies Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of a Securities Fraud Class Action Deadline on November 2, 2026 - GlobeNewswire Inc.
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hims Hers Health Inc-Aktie (HIMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Officer |
Oct 01 '26 |
Proposed Sale |
29.70 |
2,000 |
59,400 |
0 |
| Boughton Soleil | Chief Legal Officer |
Sep 30 '26 |
Sale |
29.17 |
3,461 |
100,957 |
300,809 |
| Boughton Soleil | Officer |
Sep 30 '26 |
Proposed Sale |
29.17 |
3,461 |
100,957 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 22 '26 |
Sale |
29.95 |
29,277 |
876,846 |
236,527 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 22 '26 |
Option Exercise |
5.01 |
14,000 |
70,140 |
265,804 |
| Okupe Oluyemi | Officer |
Sep 22 '26 |
Proposed Sale |
29.95 |
29,277 |
876,846 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 17 '26 |
Sale |
28.82 |
12,313 |
354,861 |
251,804 |
| Okupe Oluyemi | Officer |
Sep 17 '26 |
Proposed Sale |
28.82 |
12,313 |
354,861 |
0 |
| Boughton Soleil | Chief Legal Officer |
Sep 16 '26 |
Sale |
27.86 |
6,236 |
173,735 |
304,270 |
| Boughton Soleil | Officer |
Sep 16 '26 |
Proposed Sale |
27.86 |
6,236 |
173,735 |
0 |
1.27%
18.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):